Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]
<p>Abstract</p> <p>Background</p> <p>Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high incidence of coronary hea...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2001-07-01
|
| Series: | Current Controlled Trials in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | http://cvm.controlled-trials.com/content/2/4/195 |